EP0943336A1 — Peptide-containing pharmaceutical compositions for oral administration
Assigned to Dott Co Ltd · Expires 1999-09-22 · 27y expired
What this patent protects
The present invention provides a pharmaceutical composition for oral administration containing physiologically active peptide such as peptide hormones, opioid peptides, physiologically active proteins, enzyme proteins and the like, with an excellent stability and enhanced absorpt…
USPTO Abstract
The present invention provides a pharmaceutical composition for oral administration containing physiologically active peptide such as peptide hormones, opioid peptides, physiologically active proteins, enzyme proteins and the like, with an excellent stability and enhanced absorption via the oral route. More specifically, the invention provides a peptide-containing pharmaceutical composition for oral administration prepared as an enteric coated preparation, wherein an effective dose of physiologically active peptide is dispersed in a physiologically acceptable porous powdery or crystalline polyvalent metal compound carrier with a mean particle diameter of 500 µm or less, i.e., divalent or higher valency metal compound such as aluminum, calcium, magnesium, silicon, iron and zinc compounds. The pharmaceutical composition for oral administration according to the present invention enhances the absorption of physiologically active peptides that normally show poor absorption via the oral route.
Drugs covered by this patent
- Linzess (LINACLOTIDE) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.